tiprankstipranks
Genetic Technologies Ltd (GENE)
NASDAQ:GENE

Genetic Technologies (GENE) Stock Price & Analysis

464 Followers

GENE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.80 - $6.00
Previous Close$2.71
Volume36.48K
Average Volume (3M)29.02K
Market Cap
$10.16M
Enterprise Value$5.37M
Total Cash (Recent Filing)AU$7.87M
Total Debt (Recent Filing)AU$532.85K
Price to Earnings (P/E)>-0.1
Beta1.14
Aug 29, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-28.65
Shares Outstanding3,847,219
10 Day Avg. Volume43,087
30 Day Avg. Volume29,024
Standard Deviation0.22
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.31
Price to Sales (P/S)1.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

0.00%0.07%0.00%99.93%
0.00%
Insiders
0.00% Other Institutional Investors
99.93% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

GENE FAQ

What was Genetic Technologies Ltd’s price range in the past 12 months?
Genetic Technologies Ltd lowest stock price was $1.80 and its highest was $6.00 in the past 12 months.
    What is Genetic Technologies Ltd’s market cap?
    Currently, no data Available
    When is Genetic Technologies Ltd’s upcoming earnings report date?
    Genetic Technologies Ltd’s upcoming earnings report date is Aug 29, 2024 which is in 154 days.
      How were Genetic Technologies Ltd’s earnings last quarter?
      Genetic Technologies Ltd released its earnings results on Feb 23, 2024. The company reported -$0.836 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.836.
        Is Genetic Technologies Ltd overvalued?
        According to Wall Street analysts Genetic Technologies Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Genetic Technologies Ltd pay dividends?
          Genetic Technologies Ltd does not currently pay dividends.
          What is Genetic Technologies Ltd’s EPS estimate?
          Genetic Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Genetic Technologies Ltd have?
          Genetic Technologies Ltd has 3,847,242 shares outstanding.
            What happened to Genetic Technologies Ltd’s price movement after its last earnings report?
            Genetic Technologies Ltd reported an EPS of -$0.836 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Genetic Technologies Ltd?
              Currently, no hedge funds are holding shares in GENE
              ---

              Genetic Technologies Stock Smart Score

              Company Description

              Genetic Technologies Ltd

              Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              BioNano Genomics
              Advaxis
              Onconova Therapeutics
              Sangamo Biosciences
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis